Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adhera Therapeutics, Inc.MRNA · Entity 127789 | Director · Chief Commercial Officer | July 10, 2018 | July 12, 2018 |
| Apimeds Pharmaceuticals US, Inc.APUS · Entity 8263 | Director · Chief Executive Officer | October 15, 2025 | October 17, 2025 |
| Odyssey Health, Inc.ODYY · Entity 8618 | Chief Commerical Officer | January 16, 2024 | January 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adhera Therapeutics, Inc.
Report date July 10, 2018 · Filed July 12, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2028-07-10 | Direct | 1,125,000 |
Reported balance
After 2018-07-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-10 · Grant · Acquired 1,125,000 · Balance 1,125,000 F1: Options to purchase 187,500 shares of common stock are exercisable immediately, options to purchase 187,500 shares of common stock are exercisable on each of July 10, 2019, July 10, 2020 and July 10, 2021, options to purchase 187,500 shares of common stock shall vest on such date, if any, as the Issuer determines that it has achieved net product revenue in the amount of not less than $1.2 million for the portion of the 2018 fiscal year following June 18, 2018, and options to purchase 187,500 shares of common stock shall vest on such date, if any, as the Issuer determines that the daily VWAP of the common stock of the Issuer was not less than $2.00 per share for a sixty consecutive day period beginning on any calendar day during the 2018 fiscal year on or after June 18, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 187,500 shares of common stock are exercisable immediately, options to purchase 187,500 shares of common stock are exercisable on each of July 10, 2019, July 10, 2020 and July 10, 2021, options to purchase 187,500 shares of common stock shall vest on such date, if any, as the Issuer determines that it has achieved net product revenue in the amount of not less than $1.2 million for the portion of the 2018 fiscal year following June 18, 2018, and options to purchase 187,500 shares of common stock shall vest on such date, if any, as the Issuer determines that the daily VWAP of the common stock of the Issuer was not less than $2.00 per share for a sixty consecutive day period beginning on any calendar day during the 2018 fiscal year on or after June 18, 2018.
Apimeds Pharmaceuticals US, Inc.
Report date October 15, 2025 · Filed October 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2035-10-15 | Direct | 215,000 |
Reported balance
After 2025-10-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-15 · Grant · Acquired 215,000 · Balance 215,000 F1: The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's service to the issuer continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the issuer's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full upon the occurrence of a Change in Control, as defined in the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's service to the issuer continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the issuer's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full upon the occurrence of a Change in Control, as defined in the Plan.
Odyssey Health, Inc.
Report date January 16, 2024 · Filed January 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.09 · Expires 2034-01-15 | Direct | 37,500 |
Reported balance
After 2024-01-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-16 · Grant · Acquired 37,500 · Balance 37,500 F1: The non-qualified stock options are granted outside the Amended and Restated 2021 Omnibus Stock Incentive Plan, vesting immediately and the exercise price is the closing price on the date of the grant, January 16, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The non-qualified stock options are granted outside the Amended and Restated 2021 Omnibus Stock Incentive Plan, vesting immediately and the exercise price is the closing price on the date of the grant, January 16, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 15, 2025 Filed Oct 17, 2025 22:37 UTC | Apimeds Pharmaceuticals US, Inc. APUS · Entity 8263 | GrantStock Option (right to buy) · Derivative | 215,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001710496-25-000002 · primary_doc.xml · derivative · entry 1 Emerson Erik C. · CIK 0001710496 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock, par value $0.01 per share · 215,000 shares Expires 2035-10-15 F1 · derivative.exercise_date: The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's service to the issuer continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the issuer's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full upon the occurrence of a Change in Control, as defined in the Plan. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:56 UTC | Apimeds Pharmaceuticals US, Inc. APUS · Entity 8263 | GrantStock option (right to buy) · Derivative | 347,279 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001474506-25-000099 · primary_doc.xml · derivative · entry 2 Emerson Erik C. · CIK 0001710496 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,279 Underlying: Common Stock, par value $0.01 per share · 347,279 shares Expires 2035-05-16 F1 · derivative.exercise_date: Forty percent (40%) of the options vested immediately upon grant, and the remainder will vest in three equal annual installments beginning on 05/16/2026. The reporting person has agreed not to sell any shares underlying the options, even if exercised, for a period of three years from the date of grant. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:56 UTC | Apimeds Pharmaceuticals US, Inc. APUS · Entity 8263 | GrantCommon Stock, par value $0.01 per share | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001474506-25-000099 · primary_doc.xml · nonDerivative · entry 1 Emerson Erik C. · CIK 0001710496 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 17:10 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.09 Strike: $0.09 | $3,187.50 |
DisclosureSEC source: 0001683168-24-000340 · ownership.xml · derivative · entry 1 Emerson Erik C. · CIK 0001710496 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2034-01-15 F1 · shares: The non-qualified stock options are granted outside the Amended and Restated 2021 Omnibus Stock Incentive Plan, vesting immediately and the exercise price is the closing price on the date of the grant, January 16, 2024. F1 · derivative.underlying_shares: The non-qualified stock options are granted outside the Amended and Restated 2021 Omnibus Stock Incentive Plan, vesting immediately and the exercise price is the closing price on the date of the grant, January 16, 2024. F1 · balance_after: The non-qualified stock options are granted outside the Amended and Restated 2021 Omnibus Stock Incentive Plan, vesting immediately and the exercise price is the closing price on the date of the grant, January 16, 2024. Read SEC document |
| December 29, 2023 Filed Jan 2, 2024 17:10 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.10 Strike: $0.10 | $20,000.00 |
DisclosureSEC source: 0001683168-24-000026 · ownership.xml · derivative · entry 1 Emerson Erik C. · CIK 0001710496 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-12-28 F1 · shares: The options vest immediately and the exercise price is the closing price on the date of the grant, December 29, 2023 F1 · derivative.underlying_shares: The options vest immediately and the exercise price is the closing price on the date of the grant, December 29, 2023 F1 · balance_after: The options vest immediately and the exercise price is the closing price on the date of the grant, December 29, 2023 Read SEC document |
| November 01, 2022 Filed Nov 23, 2022 16:02 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantStock Option - Right to buy · Derivative | 475,000 | $0.25 Strike: $0.25 | $118,750.00 |
DisclosureSEC source: 0001683168-22-008022 · ownership.xml · derivative · entry 2 Emerson Erik C. · CIK 0001710496 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 475,000 shares Expires 2032-10-31 F1 · date: Vesting is as follows: 125,000 vest upon signing of this agreement; 300,000 vest upon a financing by the Company in the amount of $5,000,000 or more; 175,000 vest upon the listing of the Company on a national exchange such as Nasdaq or the NYSE. F1 · deemedExecutionDate: Vesting is as follows: 125,000 vest upon signing of this agreement; 300,000 vest upon a financing by the Company in the amount of $5,000,000 or more; 175,000 vest upon the listing of the Company on a national exchange such as Nasdaq or the NYSE. F1 · derivative.exercise_date: Vesting is as follows: 125,000 vest upon signing of this agreement; 300,000 vest upon a financing by the Company in the amount of $5,000,000 or more; 175,000 vest upon the listing of the Company on a national exchange such as Nasdaq or the NYSE. F1 · balance_after: Vesting is as follows: 125,000 vest upon signing of this agreement; 300,000 vest upon a financing by the Company in the amount of $5,000,000 or more; 175,000 vest upon the listing of the Company on a national exchange such as Nasdaq or the NYSE. Read SEC document |
| November 01, 2022 Filed Nov 23, 2022 16:02 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantStock Option - Right to buy · Derivative | 125,000 | $0.25 Strike: $0.25 | $31,250.00 |
DisclosureSEC source: 0001683168-22-008022 · ownership.xml · derivative · entry 1 Emerson Erik C. · CIK 0001710496 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-10-31 F1 · date: Vesting is as follows: 125,000 vest upon signing of this agreement; 300,000 vest upon a financing by the Company in the amount of $5,000,000 or more; 175,000 vest upon the listing of the Company on a national exchange such as Nasdaq or the NYSE. F1 · balance_after: Vesting is as follows: 125,000 vest upon signing of this agreement; 300,000 vest upon a financing by the Company in the amount of $5,000,000 or more; 175,000 vest upon the listing of the Company on a national exchange such as Nasdaq or the NYSE. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 17:00 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | GrantOptions to purchase common stock · Derivative | 1,125,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001493152-18-009946 · ownership.xml · derivative · entry 1 Emerson Erik · CIK 0001710496 · Director · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,125,000 Underlying: common stock · 1,125,000 shares Expires 2028-07-10 F1 · derivative.exercise_date: Options to purchase 187,500 shares of common stock are exercisable immediately, options to purchase 187,500 shares of common stock are exercisable on each of July 10, 2019, July 10, 2020 and July 10, 2021, options to purchase 187,500 shares of common stock shall vest on such date, if any, as the Issuer determines that it has achieved net product revenue in the amount of not less than $1.2 million for the portion of the 2018 fiscal year following June 18, 2018, and options to purchase 187,500 shares of common stock shall vest on such date, if any, as the Issuer determines that the daily VWAP of the common stock of the Issuer was not less than $2.00 per share for a sixty consecutive day period beginning on any calendar day during the 2018 fiscal year on or after June 18, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.